Pulmocide Grows Cash Pile For Promising Antifungal
Opelconazole In Phase III For Invasive Pulmonary Aspergillosis
Executive Summary
The UK firm has announced an extension of its series C financing which means it has raised just shy of $150m in the last 18 months to fund clinical development, manufacturing scale-up and preparations for the potential commercialization of opelconazole.
You may also be interested in...
F2G Tops Up Funds For Launch Of New Class Of Antifungal
Having banked a $100m upfront fee from licensing partner Shionogi a couple of months ago, F2G has now unveiled a $70m financing to advance its late-stage novel oral antifungal, olorofim.
AlzeCure Confident Of Bagging Partner For Pain Drug
The Swedish biotech is stepping up its business development plans ahead of a mid-stage readout in the summer for ACD440, its TRPV1 antagonist for neuropathic pain.
Pfizer In Pole Position To Benefit From Novartis Sickle Cell Drug Setback
Pfizer joined Novartis as the market leader in sickle cell disease when it acquired Global Blood Therapeutics last year. The US giant's Oxbryta may now move ahead following a clinical and regulatory setback for the Swiss major's Adakveo.